Evidence map›Paper›PMID 36632958›Full record

ArticleBiochemical pharmacology2023

A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance.

J M C Brown, M Zaben, C Ormonde, F Sharouf, R Spencer, H Bhatt, F A Siebzehnrubl, W P Gray

Open access · hybridAbstract read
In one paragraph

Article in Biochemical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Emerging roles of 3D-culture systems in tackling tumor drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

J M C BrownDivision of Psychological Medicine and Clinical Neurosciences, University Hospital Wales, Cardiff and Vale University Health Board, CF14 4XW, United Kingdom.
M ZabenDivision of Psychological Medicine and Clinical Neurosciences, University Hospital Wales, Cardiff and Vale University Health Board, CF14 4XW, United Kingdom; Department of Neurosurgery, University Hospital of Wales, Cardiff, United Kingdom; B.R.A.I.N Biomedical Research Unit, Cardiff University, United Kingdom.
C OrmondeDivision of Psychological Medicine and Clinical Neurosciences, University Hospital Wales, Cardiff and Vale University Health Board, CF14 4XW, United Kingdom; B.R.A.I.N Biomedical Research Unit, Cardiff University, United Kingdom.
F SharoufDivision of Psychological Medicine and Clinical Neurosciences, University Hospital Wales, Cardiff and Vale University Health Board, CF14 4XW, United Kingdom; Department of Neurosurgery, University Hospital of Wales, Cardiff, United Kingdom; B.R.A.I.N Biomedical Research Unit, Cardiff University, United Kingdom.
R SpencerDivision of Psychological Medicine and Clinical Neurosciences, University Hospital Wales, Cardiff and Vale University Health Board, CF14 4XW, United Kingdom; Department of Neurosurgery, University Hospital of Wales, Cardiff, United Kingdom; B.R.A.I.N Biomedical Research Unit, Cardiff University, United Kingdom.
H BhattDepartment of Neurosurgery, University Hospital of Wales, Cardiff, United Kingdom.
F A SiebzehnrublSchool of Biosciences, European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, United Kingdom. Electronic address: fas@cardiff.ac.uk.
W P GrayDivision of Psychological Medicine and Clinical Neurosciences, University Hospital Wales, Cardiff and Vale University Health Board, CF14 4XW, United Kingdom; Department of Neurosurgery, University Hospital of Wales, Cardiff, United Kingdom; B.R.A.I.N Biomedical Research Unit, Cardiff University, United Kingdom. Electronic address: graywp@cardiff.ac.uk.
Cardiff University · GBUniversity Hospital of Wales · GBCardiff and Vale University Health Board · GB

Funding

Medical Research Council MR/L010305/1Medical Research Council MR/S007709/1
6 · The paper itself

Abstract

Glioblastoma is among the most lethal cancers, with no known cure. A multitude of therapeutics are being developed or in clinical trials, but currently there are no ways to predict which patient may benefit the most from which drug. Assays that allow prediction of the tumor's response to anti-cancer drugs may improve clinical decision-making. Here, we present a high-density 3D primary cell culture model for short-term testing from resected glioblastoma tissue that is set up on the day of surgery, established within 7 days and viable for at least 3 weeks. High-density 3D cultures contain tumor and host cells, including microglia, and retain key histopathological characteristics of their parent tumors, including proliferative activity, expression of the marker GFAP, and presence of giant cells. This provides a proof-of-concept that 3D primary cultures may be useful to model tumor heterogeneity. Importantly, we show that high-density 3D cultures can be used to test chemotherapy response within a 2-3-week timeframe and are predictive of patient response to Temozolomide therapy. Thus, primary high-density 3D cultures could be a useful tool for brain cancer research and prediction of therapeutic resistance.

Indexed as

Antineoplastic AgentsBrain NeoplasmsGlioblastomaCell Line, TumorDrug Resistance, NeoplasmHumansTemozolomideAntineoplastic AgentsTemozolomideIn vitroPersonalized medicinePrecision medicinePreclinical models

Identifiers

PMID36632958
PMCPMC10840506
OpenAlexW4313830121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.